Bluefin Capital Management’s Amedisys AMED Stock Holding History

Bluefin Capital Management’s Portfolio AMED Stock Details AMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-4,013	Closed	-$372K	–	143
2025 Q1	$372K	Buy	+4,013	New	+$370K	0.27%	50

Other funds holding AMED

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TAL

TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Bluefin Capital Management's AMED Position: Q2 2025 in Review

Bluefin Capital Management sold out of Amedisys (AMED) in Q2 2025, closing a stake of 4,013 shares — an estimated $372K sold.

Bluefin Capital Management first reported a position in AMED in Q1 2025 and held it in 1 quarter. The position peaked at $372K in Q1 2025. 319 funds tracked by Wall St. Rank hold AMED as of Q2 2025.

Bluefin Capital Management reported no remaining Amedisys position as of Q2 2025 after selling out during the quarter.
Bluefin Capital Management sold 4,013 Amedisys shares in Q2 2025, an estimated $372K.
Bluefin Capital Management first reported a position in Amedisys in Q1 2025 and held it in 1 quarter.
Bluefin Capital Management's Amedisys position peaked at $372K in Q1 2025.
319 funds tracked by Wall St. Rank held Amedisys as of Q2 2025.

Based on Bluefin Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.